Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine, Cytarabine and ATO in p53-mutated AML
NCT03381781Phase 2Unknown
- Start
- Mar 2018
- Primary completion
- Nov 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in acute myeloid leukemia (AML). Primary endpoint: Relapse Free Survival. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03381781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381781.